Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers

BACKGROUND: Dimethyl fumarate (DMF) and fingolimod (FTY) are approved oral disease-modifying therapies for relapsing multiple sclerosis (MS). Observational studies are valuable when randomized clinical trials cannot be done due to ethical or practical reasons. Two-site studies allow investigators to...

Descripción completa

Detalles Bibliográficos
Autores principales: Vollmer, Brandi, Ontaneda, Daniel, Bandyopadhyay, Anasua, Cohn, Sam, Nair, Kavita, Sillau, Stefan, Bermel, Robert A., Corboy, John R., Fox, Robert J., Vollmer, Timothy, Cohen, Jeffrey A., Alvarez, Enrique, Hersh, Carrie M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6105060/
https://www.ncbi.nlm.nih.gov/pubmed/30140580
http://dx.doi.org/10.1212/CPJ.0000000000000487

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6105060/
https://www.ncbi.nlm.nih.gov/pubmed/30140580
http://dx.doi.org/10.1212/CPJ.0000000000000487

Ejemplares similares